Robert F. Kennedy Jr. announced a drug policy on a podcast. The FDA is now scheduling the meeting to approve it.
That is the short version of what happened when the health and human services secretary appeared on The Joe Rogan Experience in late February and said he would restore legal access to a class of compounds called peptides — substances that fitness influencers have popularized as injury and anti-aging treatments, and that some physicians have prescribed off-label for years. The FDA's scientific advisory committee did not ask for this. It did not recommend it. It had not completed its review. The secretary spoke first.
On July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee will meet to discuss placing seven peptide ingredients back on the list of bulk drug substances that licensed compounding pharmacies are allowed to use. The meeting is listed on the FDA's website. The agenda is public. What is less clear is whether the committee's role is to evaluate the science — or to ratify a decision that was already made.
The compounds in question are short chains of amino acids, the building blocks of proteins. Peptides occur naturally in the body and can be synthesized to mimic or amplify biological signals — growth hormone release, immune modulation, tissue repair. Some, like insulin and GLP-1 agonists such as semaglutide, are FDA-approved drugs with decades of clinical data behind them. Others, including a group that includes BPC-157, thymosin beta-4, and a family of compounds called growth-hormone-releasing peptides, have limited human trial data. They have been used in clinics and prescribed by physicians, but they have not been through the large randomized trials required for FDA approval.
In September 2023, the FDA moved 19 of these substances to Category 2 — effectively blocking compounding pharmacies from preparing them. The agency cited potential safety concerns including immune reactions, impurities from unregulated manufacturing, and insufficient clinical data to establish safe dosing. The decision was administrative, made under an interim policy framework.
Then the nominations for several of those peptides were withdrawn in September 2024, removing five from Category 2 through a procedural mechanism unrelated to FDA policy reversal. That left the remaining compounds — including some of the most widely used in the peptide-clinic world, among them BPC-157 and thymosin beta-4 — in Category 2.
On February 27, 2026, Kennedy appeared on Joe Rogan's podcast and said HHS would move those remaining compounds back to Category 1 — the designation that allows compounding pharmacies to prepare them under a physician's prescription. The announcement generated significant attention in the peptide-clinic industry and among patient advocates who had argued the 2023 restrictions cut off access to compounds that were helping people.
As of mid-April 2026, the FDA has not published a formal rule reflecting Kennedy's announcement. The Pharmacy Compounding Advisory Committee has not completed its review of the affected substances. The seven-peptide agenda for the July meeting suggests a staged reclassification — the first batch of a broader set of decisions.
The committee's role is nominally advisory. It evaluates bulk drug substances nominated for the 503A bulks list — the list governing what traditional compounding pharmacies can prepare — and makes recommendations to the FDA. The FDA is not bound to follow the committee's advice. But the committee is the agency's primary scientific forum for these decisions, and its recommendations carry significant weight in the rulemaking record.
Whether Kennedy's announcement pre-determined what the committee will recommend is the question this story cannot fully answer from public records. HHS sets the FDA's priorities and budget. A politically appointed secretary who announces an outcome before the scientific review is complete is behaving unusually — but whether that behavior changes what the committee does requires access to internal deliberations that are not public.
What is knowable from public records is the sequence: announcement first, process second. And that sequence is itself the story.
The FDA declined to comment for this article. HHS did not respond to a request for comment on the timeline between Kennedy's announcement and the committee's meeting.
The advisory committee will hear from advocates and researchers on both sides. Peptide-clinic operators and patient groups argue that the 2023 restrictions cut off access to compounds with legitimate clinical use and decades of safety data from physician-monitored patients. Researchers who study peptide safety argue that the lack of large clinical trials is not evidence of safety — it is evidence of absent data, and those are different things.
What happens after the July meeting depends on what the committee recommends and whether the FDA acts on it. The formal rulemaking process — notice, comment, final rule — can take years. The practical effect of Kennedy's announcement may be that the FDA's review moves faster than it would have without the political signal. Or it may be that nothing changes until the rule is formally published.
The broader question — whether a health secretary's podcast appearance now constitutes the opening move in a regulatory process — is one that the FDA's own institutional history does not have a clear answer to. HHS secretaries have spoken publicly about regulatory priorities before. They have not typically announced specific reclassification decisions on podcasts before the scientific advisory process has reported in.
The July meeting is listed on FDA.gov. The webcast will be open to the public. Whether what happens inside it is science or performance is the question worth sitting with.
https://www.statnews.com/2026/04/15/peptides-fda-panel-to-discuss-broader-access-compounding/
https://www.nytimes.com/2026/03/31/health/peptide-ban-fda-rfk-jr.html
https://www.propublica.org/article/peptide-safety-fda-compounding-pharmacies
https://formblends.com/articles/safety-hub/fda-peptide-ban-legal-status-2026
